Related references
Note: Only part of the references are listed.Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7
D. Lashley et al.
NEUROLOGY (2010)
Congenital myasthenic Syndromes
Joseph H. Nogajski et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
REFINEMENT OF THE CLINICAL PHENOTYPE INMUSK-RELATED CONGENITAL MYASTHENIC SYNDROMES
V. Mihaylova et al.
NEUROLOGY (2009)
Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations
U. Schara et al.
NEUROMUSCULAR DISORDERS (2009)
Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders
Anne Michalk et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes
Violeta Mihaylova et al.
BRAIN (2008)
Congenital Myasthenic Syndromes in childhood: Diagnostic and management challenges
M. Kinali et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa
P. Richard et al.
NEUROLOGY (2008)
Clinical features of the DOK7 neuromuscular junction synaptopathy
Jacqueline Palace et al.
BRAIN (2007)
Current understanding of congenital myasthenic syndromes
AG Engel et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Distinct phenotypes of congenital acetylcholine receptor deficiency
G Burke et al.
NEUROMUSCULAR DISORDERS (2004)
Mutations in congenital myasthenic syndromes reveal an ε subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR
J Ealing et al.
HUMAN MOLECULAR GENETICS (2002)
Share Paper
